Trial Condition(s):

Uterine bleeding profile prediction

A study to learn more about how a smartphone app called MyIUS predicts future menstrual bleeding in women after they have begun using intrauterine birth control method (a birth control device is inserted into a woman’s uterus by her doctor) (MyIUS)

Bayer Identifier:

21424

ClinicalTrials.gov Identifier:

NCT04989595

EudraCT Number:

Not Available

EU CT Number:

Not Available

Study Completed

Trial Purpose

Researchers are looking to learn more about future menstrual bleeding in women who have started using intrauterine contraception methods. “Intrauterine contraception” means that a device is inserted into a woman’s uterus by her doctor. The device then releases a birth control treatment into the uterus.
Researchers have found that when women use intrauterine contraception, its effects on the menstrual cycle can cause changes to how often and for how long women will bleed. This is one of reasons women may stop using their intrauterine contraception.
So, the researchers in this study wanted to learn about a tool that can be used to predict future bleeding events. This tool was developed based on the results of previous clinical studies that researched menstrual bleeding. This tool is a smartphone application called MyIUS.
This study will include about 3,000 women who have recently had intrauterine contraception inserted and who use the MyIUS app.
There will be no visits with a study doctor in this study. After the intrauterine contraception has been inserted, the women will start to record any events of bleeding in the MyIUS app. After they have recorded events of bleeding for a total of 90 days, the MyIUS app will give a prediction of menstrual bleeding expected for the next 180 days. The women who sign the electronic informed consent form will continue to record their bleeding events for a total of 6 months.
The researchers will then collect this information. They will use this information to find out how well the MyIUS app can predict future menstrual bleeding.

Inclusion Criteria
- Insertion of Kyleena, Jaydess, or Mirena IUS
- Female (of legal age to provide electronic informed consent (eIC)) using the MyIUS app
- Submitted eIC to use all data documented in the MyIUS app
Exclusion Criteria
- None

Trial Summary

Enrollment Goal
3045
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Kyleena (Levonorgestrel, BAY86-5028)
Accepts Healthy Volunteers
Yes

Where to Participate

Loading...
Locations
Locations
Locations

Many Locations

Many Locations, Denmark

Locations

Many Locations

Many Locations, Sweden

Locations

Many Locations

Many Locations, Germany

Locations

Many Locations

Many Locations, Spain

Locations

Many Locations

Many Locations, Mexico

Locations

Many Locations

Many Locations, Brazil

Trial Design